» Articles » PMID: 35912165

Diagnosis and Clinical Management of Chagas Disease: An Increasing Challenge in Non-Endemic Areas

Overview
Publisher Dove Medical Press
Date 2022 Aug 1
PMID 35912165
Authors
Affiliations
Soon will be listed here.
Abstract

Chagas disease (CD) is caused by the parasite , and it is endemic in Central, South America, Mexico and the South of the United States. It is an important cause of early mortality and morbidity, and it is associated with poverty and stigma. A third of the cases evolve into chronic cardiomyopathy and gastrointestinal disease. The infection is transmitted vertically and by blood/organ donation and can reactivate with immunosuppression. Case identification requires awareness and screening programmes targeting the population at risk (women in reproductive age, donors, immunocompromised patients). Treatment with benznidazole or nifurtimox is most effective in the acute phase and prevents progression to chronic phase when given to children. Treating women antenatally reduces but does not eliminate vertical transmission. Treatment is poorly tolerated, contraindicated during pregnancy, and has little effect modifying the disease in the chronic phase. Screening is easily performed with serology. Migration has brought the disease outside of the endemic countries, where the transmission continues vertically and via blood and tissue/organ donations. There are more than 32 million migrants from Latin America living in non-endemic countries. However, the infection is massively underdiagnosed in this setting due to the lack of awareness by patients, health authorities and professionals. Blood and tissue donation screening policies have significantly reduced transmission in endemic countries but are not universally established in the non-endemic setting. Antenatal screening is not commonly done. Other challenges include difficulties accessing and retaining patients in the healthcare system and lack of specific funding for the interventions. Any strategy must be accompanied by education and awareness campaigns directed to patients, professionals and policy makers. The involvement of patients and their communities is central and key for success and must be sought early and actively. This review proposes strategies to address challenges faced by non-endemic countries.

Citing Articles

Redefining the treatment of Chagas disease: a review of recent clinical and pharmacological data for a novel formulation of nifurtimox.

Altcheh J, Grossmann U, Stass H, Springsklee M, Garcia-Bournissen F PLoS Negl Trop Dis. 2025; 19(2):e0012849.

PMID: 39999088 PMC: 11856279. DOI: 10.1371/journal.pntd.0012849.


Antiparasitic Activity of Narciclasine and Evaluation of Its Effects on Plasma Membrane and Mitochondria of .

Gomes K, Costa-Silva T, Borges W, Andrade B, Ferreira D, Tempone A ACS Omega. 2025; 10(3):3025-3032.

PMID: 39895773 PMC: 11780464. DOI: 10.1021/acsomega.4c09867.


Nucleoside Analogues for Chagas Disease and Leishmaniasis Therapy: Current Status and Future Perspectives.

Nwoke E, Lowe S, Aldabbagh F, Kalesh K, Kadri H Molecules. 2024; 29(22).

PMID: 39598623 PMC: 11596272. DOI: 10.3390/molecules29225234.


Assessment of Alinity s Chagas as a Primary Diagnostic Test for Chronic Chagas Disease in a Non-Endemic Area of Europe (Barcelona, Spain).

Abras A, Ballart C, Fernandez-Arevalo A, Llovet T, Gallego M, Munoz C Life (Basel). 2024; 14(10).

PMID: 39459578 PMC: 11509444. DOI: 10.3390/life14101278.


Diversity of Chagas disease diagnostic antigens: Successes and limitations.

Bhattacharyya T, Murphy N, Miles M PLoS Negl Trop Dis. 2024; 18(10):e0012512.

PMID: 39352878 PMC: 11444392. DOI: 10.1371/journal.pntd.0012512.


References
1.
Meneghelli U . Chagasic enteropathy. Rev Soc Bras Med Trop. 2004; 37(3):252-60. DOI: 10.1590/s0037-86822004000300012. View

2.
Angheben A, Boix L, Buonfrate D, Gobbi F, Bisoffi Z, Pupella S . Chagas disease and transfusion medicine: a perspective from non-endemic countries. Blood Transfus. 2015; 13(4):540-50. PMC: 4624528. DOI: 10.2450/2015.0040-15. View

3.
Rodari P, Angheben A, Gennati G, Trezzi L, Bargiggia G, Maino M . Congenital Chagas disease in a non-endemic area: Results from a control programme in Bergamo province, Northern Italy. Travel Med Infect Dis. 2018; 25:31-34. DOI: 10.1016/j.tmaid.2018.04.011. View

4.
Murcia L, Carrilero B, Munoz-Davila M, Thomas M, Lopez M, Segovia M . Risk factors and primary prevention of congenital Chagas disease in a nonendemic country. Clin Infect Dis. 2012; 56(4):496-502. DOI: 10.1093/cid/cis910. View

5.
Torrico F, Alonso-Vega C, Suarez E, Rodriguez P, Torrico M, Dramaix M . Maternal Trypanosoma cruzi infection, pregnancy outcome, morbidity, and mortality of congenitally infected and non-infected newborns in Bolivia. Am J Trop Med Hyg. 2004; 70(2):201-9. View